Enzo Biochem Cash on Hand 2010-2023 | ENZ
Enzo Biochem cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Enzo Biochem Annual Cash on Hand
(Millions of US $) |
| 2022 |
$22 |
| 2021 |
$44 |
| 2020 |
$48 |
| 2019 |
$60 |
| 2018 |
$60 |
| 2017 |
$64 |
| 2016 |
$68 |
| 2015 |
$18 |
| 2014 |
$17 |
| 2013 |
$9 |
| 2012 |
$15 |
| 2011 |
$24 |
| 2010 |
$34 |
| 2009 |
$50 |
Enzo Biochem Quarterly Cash on Hand
(Millions of US $) |
| 2023-01-31 |
$5 |
| 2022-10-31 |
$12 |
| 2022-07-31 |
$22 |
| 2022-04-30 |
$31 |
| 2022-01-31 |
$34 |
| 2021-10-31 |
$36 |
| 2021-07-31 |
$44 |
| 2021-04-30 |
$45 |
| 2021-01-31 |
$45 |
| 2020-10-31 |
$46 |
| 2020-07-31 |
$48 |
| 2020-04-30 |
$54 |
| 2020-01-31 |
$52 |
| 2019-10-31 |
$57 |
| 2019-07-31 |
$60 |
| 2019-04-30 |
$64 |
| 2019-01-31 |
$42 |
| 2018-10-31 |
$53 |
| 2018-07-31 |
$60 |
| 2018-04-30 |
$63 |
| 2018-01-31 |
$64 |
| 2017-10-31 |
$67 |
| 2017-07-31 |
$64 |
| 2017-04-30 |
$63 |
| 2017-01-31 |
$62 |
| 2016-10-31 |
$67 |
| 2016-07-31 |
$68 |
| 2016-04-30 |
$32 |
| 2016-01-31 |
$37 |
| 2015-10-31 |
$31 |
| 2015-07-31 |
$18 |
| 2015-04-30 |
$14 |
| 2015-01-31 |
$15 |
| 2014-10-31 |
$17 |
| 2014-07-31 |
$17 |
| 2014-04-30 |
$15 |
| 2014-01-31 |
$8 |
| 2013-10-31 |
$7 |
| 2013-07-31 |
$9 |
| 2013-04-30 |
$6 |
| 2013-01-31 |
$10 |
| 2012-10-31 |
$13 |
| 2012-07-31 |
$15 |
| 2012-04-30 |
$15 |
| 2012-01-31 |
$19 |
| 2011-10-31 |
$21 |
| 2011-07-31 |
$24 |
| 2011-04-30 |
$28 |
| 2011-01-31 |
$31 |
| 2010-10-31 |
$32 |
| 2010-07-31 |
$34 |
| 2010-04-30 |
$34 |
| 2010-01-31 |
$44 |
| 2009-10-31 |
$46 |
| 2009-07-31 |
$50 |
| 2009-04-30 |
$55 |
| 2009-01-31 |
$73 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.110B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
